Clinical Trials Logo

Clinical Trial Summary

The primary purpose of this study is to conduct a Respiratory Rate accuracy validation comparing the Spire Medical Health Tag to a FDA cleared End Tidal Carbon Dioxide monitor Reference Standard (GE Datex-Ohmeda).

After IRB approval, a minimum of 20 healthy volunteer test subjects, 18 or older will be entered into this study designed to validate the accuracy of the respiratory rate feature of the Spire Medical Health Tag (Device Under Test).

The subjects will be selected to represent a range of body types including small, average, muscular, and large with a range of BMIs. Each subject will be connected to a FDA cleared EtCO2 monitor (GE Datex-Ohmeda) and will be instrumented with a mouthpiece or open system mask that allows for measurement of EtCO2 derived respiratory rate. A range of stable respiratory rates will be elicited from each volunteer test subject with the use of a paced breathing application on a mobile phone. Subjects will also be connected to a 3-lead ECG (GE Datex-Ohmeda) for the purpose of monitoring heart rate and comparing to the pulse rate measurements recorded by the Spire Medical Health Tag.

The respiratory rate and pulse rate will be measured simultaneously for the Reference and the Device Under Test.


Clinical Trial Description

The purpose of this study is to collect data to validate the respiratory rate performance of the Medical Health Tag developed by Spire Health. The Medical Health Tag respiratory rate will be evaluated during non-motion conditions over the range a range of 5-50 breaths per minute via Reference EtCO2. A FDA cleared, GE Healthcare S5 Multi-parameter monitoring system with End Tidal Carbon Dioxide (EtCO2) and 3-lead ECG will be used for the Respiratory and Pulse Rate References. There are no risks or adverse device effects to be assessed. There are no contraindications for use in the proposed study / study population.

This study will focus on the respiratory rate, RR parameter. The Spire Medical Health Tag is investigational and has not been cleared by the FDA. The intended purpose of the device under test is spot-checking, non-invasive monitoring / logging of respiratory rate on humans. For this evaluation, the device will be run in a continuous data collection mode.

The study population will include 20 healthy competent adults, ages 18 years and older. The subject selection will be a mix of males and females with small to large physiques. The subjects must understand the study and consent to participate by signing the Informed Consent Form. The subjects must be healthy showing no evidence of medical problems as indicated by satisfactorily completing the health assessment form and passing the health screening. Eligible subjects need to meet all of the inclusion criteria and none of the exclusion criteria for participation.

It is expected that the data collection will take approximately 4-7 days to complete. There is no additional followup required for the investigation.

The data from the Device Under Test will be collected on an application installed on the iOS or Android mobile device separate from the reference equipment.

Multi-parameter monitor used during the study to observe a subject's vital signs include ECG tracing, heart rate, respiratory rate, and EtCO2 with capnograph.

- GE Healthcare S5 Compact Monitor, M-NESTPR module with ECG, and/or Multi-parameter monitor

- Portable oxygen tank, mask and ambu bag

- GE Healthcare (Datex-Ohmeda) 3900 TruTrak+ / OxyTip+ Oxy-F-UN or Oxy-AF Sensor and Oxy-OL3 cable (SpO2 monitoring)

- Blood pressure cuff and stethoscope

Currently the FDA defines respiration rate devices as Class II devices. The Device Under Test in this study is considered non-significant risk device.

There are no risks or adverse device effects to be assessed. There are no contraindications for use in the proposed study / study population. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04104737
Study type Interventional
Source Spire, Inc.
Contact
Status Completed
Phase N/A
Start date June 4, 2019
Completion date June 13, 2019

See also
  Status Clinical Trial Phase
Completed NCT03832205 - Validation of Respiratory Rate and Heart Rate Measurements by Capaciflectors Placed in Four Locations on the Chest
Completed NCT04506684 - Reveal LINQ Respiration Clinical Study
Completed NCT03685227 - A Closer Look at Yoga Nidra: Sleep Lab Analyses N/A
Completed NCT04179279 - Comparative Analysis of a Non-contact Respiratory and Heart Rate Monitor Vs. a Conventional Clinically Validated Reference Monitor
Completed NCT04077593 - On the PhonE Respiratory rAte Study (OPERA)
Completed NCT03750344 - ChroniSense Polso Wrist Worn Respiration Rate Validation Study N/A
Completed NCT05366049 - The Effect of Methods Used in Oral Antipyretic Administration on the Vital Findings of the Child With Fever N/A
Completed NCT03148873 - RespiraSense Versus Capnography & Manual Counting
Recruiting NCT05263791 - Evaluation the Non-Inferiority of Airmod to Capnostream™35 N/A
Completed NCT05246358 - Respiratory Rate Validation Study - ChroniSense Polso N/A
Recruiting NCT05812378 - Respiratory Monitoring System Safety and Performance Study
Not yet recruiting NCT06292299 - The PARS Study: Paediatric Advanced Respiratory Service Study - An Observational Diagnostic Feasibility Study
Recruiting NCT05022264 - Remote Investigation and Assessment of Vital Signs
Completed NCT06086769 - High Flow Oxygen Therapy Effect on Healthy Subjects N/A
Completed NCT04064645 - Bora Band Respiration Rate Study N/A
Completed NCT01472133 - Validation of Respiration Rate Algorithms N/A
Completed NCT03306537 - Sensor Validation Study - Quality Assurance
Active, not recruiting NCT03750318 - Validation Study on RENEW's Aingeal at KK Women's and Children's Hospital N/A
Completed NCT03754231 - Validation Study on RENEW's Aingeal at KK Women's and Children's Hospital N/A
Completed NCT04346498 - Can Kangarooing Small Babies on the Back of a Mother Keep Them Warm and Stable N/A